Cell lines

Report: Bioprocessing trends 2018-2023

08-Oct-2018 By Flora Southey

Increased cell and gene therapy production and reduced development timelines are listed among bioprocessing trends predicted over the next five years, says consultant.

Novo Nordisk sets up stem cell manufacturing in California, US

02-Oct-2018 By Flora Southey

Novo Nordisk will take over the lease of a manufacturing facility in Fremont, California, where the company will make stem cell-based therapies with optionally licensed technology.

NEWS IN BRIEF

BIA Separations adds upstream processing facility

28-Sep-2018 By Ben Hargreaves

BIA Separations has completed work on an additional upstream processing laboratory in Ajdovščina, Slovenia.

Pall collaborates with Aetos for ‘next-gen’ biosimilar manufacturing

26-Sep-2018 By Maggie Lynch

Pall has entered an agreement with Aetos Biologics to provide manufacturing solutions for expedited biosimilar development.

Thermo and Oxford Genetics expand CRISPR toolkits with ERS deals

25-Sep-2018 By Ben Hargreaves

Thermo Fisher and Oxford Genetics have announced separate plans to partner with ERS Genomics, gaining access to CRISPR gene editing technology.

CHO cells the 1900s model car in a 2020 Tesla world, says Dyadic

24-Sep-2018 By Flora Southey

Dyadic’s CHO-alternative, the C1 production platform, could reduce time and cost at almost every stage of the cell development and biomanufacturing process, says CEO.

Lonza invests $418m in two biomanufacturing solutions

21-Sep-2018 By Ben Hargreaves

Lonza announced it would invest in two new “Ibex Solutions”, which offer manufacturing capabilities to biotechs developing antibody therapies.

Thermo Fisher expands bioprocessing with BD acquisition

14-Sep-2018 By Ben Hargreaves

Thermo Fisher Scientific announced the acquisition of BD’s Advanced Bioprocessing unit, which will join its Life Sciences Solution business.

Standardised mAb production research provides ‘benchmark’ for biosimilars

22-Aug-2018 By Ben Hargreaves

NIST has progressed beyond producing the world’s first standardised mAb to make public its production methods.

LenioBio and Fraunhofer Institute to develop protein expression platform

15-Aug-2018 By Maggie Lynch

LenioBio and Fraunhofer Institute IME have entered a licensing agreement, allowing LenioBio to commercialize technology into a protein expression platform.

Regulatory eyes on Regeneron: US FDA issues CRL for Eylea

14-Aug-2018 By Flora Southey

The US Food and Drug Administration has rejected Regeneron’s eye candidate, Eylea, but the biotech says it expects a final regulatory decision within two months.

CRISPR research deal will attract new business, says Oxford Genetics

09-Aug-2018 By Flora Southey

Oxford Genetics has signed a supply and licensing agreement for CRISPR engineered mammalian cell line with an unnamed ecommerce firm.

Catalent brings in Berkeley Lights to optimise cell lines

18-Jul-2018 By Ben Hargreaves

Catalent has agreed a deal to apply Berkeley Lights’ Beacon optofluidic platform to its cell lines.

Pionyr inks second deal with ProBioGen to push antibody towards clinical trials

17-Jul-2018 By Flora Southey

ProBioGen will use its CHO.RiGHT expression platform to develop and manufacture a second antibody for Pionyr Immunotherapeutics.

NEWS IN BRIEF

Selexis and Symphogen expand partnership to progress two mAbs

11-Jul-2018 By Ben Hargreaves

Selexis and Symphogen have announced that the latter has submitted INDs for clinical programmes to progress two mAbs using Selexis’ platform.

Newcells Biotech receives £2m to advance stem cell research

04-Jul-2018 By Ben Hargreaves

Newcells Biotech announced that it has received £2m ($2.64m) from NVM Private Equity and Northstar Ventures.

Abzena signs $5.9m manufacture agreement with Telix

04-Jul-2018 By Ben Hargreaves

Abzena has revealed that it has signed a GMP manufacturing and bioconjugation deal with Telix worth $5.9m.

AbSci aims to tackle the antibody market after raising $12m to scale E. coli-based tech

20-Jun-2018 By Melissa Fassbender

With $12m in Series C financing, AbSci is looking to tackle the antibody market by accelerating innovation and driving down manufacturing costs using its synthetic biology platform, says CEO.

UK invests in cell and gene therapy workforce to prepare for commercial products

29-May-2018 By Nick Taylor

The UK is investing £3m ($4m) to build a workforce capable of delivering cell and gene therapies to patients at commercial scales.

Stem cell clinic to ‘vigorously defend’ US FDA lawsuit

23-May-2018 By Melissa Fassbender

The US Department of Justice has filed a lawsuit to stop US Stem Cell Clinic from performing autologous stem cell procedures at the request of the US Food and Drug Administration (FDA).

Lilly to bolster immuno-oncology program with Armo BioSciences purchase

14-May-2018 By Brittany Farb Gruber

In a move aimed to bolster its immuno-oncology program, Eli Lilly and Company has acquired Armo BioSciences for $50 per share, or approximately $1.6bn.

PlantForm receives European patent for tobacco plant-based platform

09-May-2018 By Brittany Farb Gruber

The patent will help PlantForm Corporation continue to advance its platform for manufacturing antibody and protein drugs, as the company looks to bring products to market, says CEO.

Recoding the human genome: Cellectis, Wyss aim to construct virus-resistant cells

08-May-2018 By Brittany Farb Gruber

Researchers at the Wyss Institute are teaming up with Cellectis to develop “ultra-safe” human cells resistant to infection – which could enable more effective ways to manufacture protein therapeutics, vaccines, and cell therapies.

Avid plans expansion with focus on biologics development

24-Apr-2018 By Melissa Fassbender

There is no slowdown in sight, says Avid Bioservices CEO, as the company today announces further expansion to support new client projects and optimize its novel CHO-based expression system.

Sanofi using Berkeley Lights’ tech to catalyze cell line development

20-Apr-2018 By Melissa Fassbender

Berkeley Lights has signed a new agreement with Sanofi through which the company will use its Beacon OptoFluidic Platform to fast-track cell line development.

Selexis says $2m investment will speed up cell bank delivery time

19-Apr-2018 By Flora Southey

Cell line developer Selexis has invested in laboratory equipment to reduce delivery times of its high expressing and stable research cell banks.

Bio-Separation: Our outgoing editor looks back over 5 years

13-Apr-2018 By Dan Stanton

Biopharma-Reporter editor Dan Stanton is finally packing his buffer bag and moving upstream.

Sanofi: €350m vaccine investment part of ‘digital factory’ ambition

13-Apr-2018 By Dan Stanton

A new vaccine manufacturing facility in Toronto, Canada will boast single-use tech and closed continuous process to help improve productivity and performance, Sanofi says.

GSK offloads gene therapy portfolio and takes stake in Orchard

12-Apr-2018 By Dan Stanton

GlaxoSmithKline has sold a number of gene therapy products – including its approved autologous ex vivo product Strimvelis – to Orchard Therapeutics.

Stellar ups aquaculture on demand for limpet protein used in vaccine production

11-Apr-2018 By Dan Stanton

Demand for a protein produced from a marine mollusk used as a carrier molecule in therapeutic vaccines has driven Stellar Biotech to expand a facility in LA.

Cell therapy demand means CMOs need to up their capabilities, PharmSource

10-Apr-2018 By Dan Stanton

There is a lack of third-party capabilities in the autologous cell therapy space says the new editor of PharmSource ahead of this year’s Interphex Convention.

KBI, ReForm partnership about ‘bringing better biologics to patients,’ says CEO

05-Apr-2018 By Melissa Fassbender

KBI will provide services to ReForm to further develop and validate its biologic formulation platform and in turn, will gain access to ReForm’s proprietary excipient technologies.

“We need Big Pharma and we are getting Big Pharma,” says Dyadic

Dyadic confident Big Biopharma will move away from CHO cell reliance

04-Apr-2018 By Dan Stanton

Dyadic International says a string of deals shows biopharma is beginning to embrace its low-cost and high-yielding – yet commercially unproven – fungus-based expression platform.

Fujifilm pays $800m for cell culture media firm Irvine Scientific

30-Mar-2018 By Dan Stanton

Fujifilm has acquired Irvine Scientific, adding a range of cell culture media to its growing bioprocessing business.

Eye complaint: Novartis sues Regeneron for Lucentis manufacturing IP breach

28-Mar-2018 By Dan Stanton

Novartis says the manufacturing method for Regeneron’s wet macular degeneration drug Eylea (aflibercept) infringes on its Lucentis (ranibizumab) patents.

Takeda’s off-the-shelf stem cell therapy approved in Europe

27-Mar-2018 By Dan Stanton

Alofisel (darvadstrocel) has become the first allogeneic stem cell product to be approved in Europe.

Tillots Pharma licenses CHO cell line tech from Lonza and BioWa

23-Mar-2018 By Staff Reporter

Lonza and BioWa’s POTELLIGENT CHOK1SV technology will be licensed by Tillots Pharma to develop its antibody pipeline.

Abzena strikes deal to access cell lines

23-Mar-2018 By Staff Reporter

Abzena has gained access to a major mammalian cell line depository it says will cut license negotiations for its customers.

CHO jumping: Samsung BioLogics to develop in-house cell line

20-Mar-2018 By Dan Stanton

Samsung BioLogics will begin offering its own CHO cell line for its customers’ development projects from 2019.

LenioBio teams with Dow for tobacco-based expression system

20-Mar-2018 By Dan Stanton

LenioBio will offer cell-free protein expression (CFPE) kits for drug screening through a partnership with DowDuPont, and says it is looking into using the tech for bioprocessing.

Novavax: Flu vaccine failings due to 'outdated' egg-based manufacturing

15-Mar-2018 By Dan Stanton

Egg adaptation is the biggest culprit in this year’s poor flu vaccine efficacy says Novavax, a firm developing a product based on recombinant protein nanoparticles.

Compugen licenses Selexis cell line tech

15-Mar-2018 By Dan Stanton

Compugen has selected Selexis’ SUREtechnology cell expression platform to generate high-performance research cell banks (RCBs) and support its antibody pipeline.

Berkeley Lights and MD Anderson launch cell therapy JV

09-Mar-2018 By Flora Southey

Berkeley Lights and MD Anderson Cancer Centre have created a company aimed at developing autologous cell therapies to treat solid tumours.

Scientists look to gene-inserting tech for T-cell modification

06-Mar-2018 By Flora Southey

A gene-inserting technology that effectively implants large molecules into cells could help modify T-cells from a patient’s immune system, says researcher.

Draper touts new bioprocessing method as ‘next big advance in CAR T-cell treatment’

02-Mar-2018 By Melissa Fassbender

Draper has designed a microfluidic transduction device (MTD) it claims will help CAR T-cell therapy developers lower costs, up efficiency – and potentially bring manufacturing to the patient’s bedside.

CEL-SCI patent allows for LEAPS vaccine platform expansion

28-Feb-2018 By Staff Reporter

A newly approved patent will allow CEL-SCI to explore using cellular delivery to prevent and treat infectious diseases using its LEAPS technology, the firm says.

Xencor extends ‘plug-and-play’ deal with Selexis, signs four mAbs

28-Feb-2018 By Flora Southey

Xencor and Selexis will extend their strategic partnership with the signing of four commercial license agreements to advance XmAb bispecific antibody drug candidates.

Dyadic enters R&D deal for its fungus-based expression system

21-Feb-2018 By Dan Stanton

“There is a new kid on the block to rival E. Coli, CHO and yeast,” says Dyadic International as it collaborates to widen the use of its C1 expression tech.

Astellas adding 'off-the-shelf' stem cell tech in $102.5m acquisition

20-Feb-2018 By Dan Stanton

Astellas will bolster its regenerative medicine arm through the acquisition of pluripotent stem cell maker Universal Cells.

Lonza rejigs network to tap 'huge potential' of cell and gene therapies

16-Feb-2018 By Dan Stanton

Lonza will combine its cell and gene therapy capabilities through four centres of excellence worldwide, following a number of investments in the space.